These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 28989886)
21. Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study. Erande S; Mukhopadhyay J; Dange A; Deogaonkar A; Birla A; Doshi C; Revankar S; B SS; Kumar N; Kadam PV Cureus; 2023 Sep; 15(9):e44548. PubMed ID: 37795066 [TBL] [Abstract][Full Text] [Related]
22. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Yokoyama H; Hirao K; Yamaguchi K; Oishi M; Lee G; Yagi N; Takamura H; Kashiwagi A Jpn Clin Med; 2014; 5():33-41. PubMed ID: 25288908 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659 [TBL] [Abstract][Full Text] [Related]
24. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. Tandon T; Dubey AK; Srivastava S; Manocha S; Arora E; Hasan N J Family Med Prim Care; 2019 Mar; 8(3):955-959. PubMed ID: 31041232 [TBL] [Abstract][Full Text] [Related]
25. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N; Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169 [TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968 [TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety of initial treatment with glimpeiride versus sitagliptin in type 2 diabetes]. Tamez-Pérez HE; Rev Med Inst Mex Seguro Soc; 2015; 53(2):142-8. PubMed ID: 25760742 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis. Hou L; Zhao T; Liu Y; Zhang Y Exp Ther Med; 2015 Apr; 9(4):1528-1536. PubMed ID: 25780464 [TBL] [Abstract][Full Text] [Related]
29. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599 [TBL] [Abstract][Full Text] [Related]
30. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125 [No Abstract] [Full Text] [Related]
31. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial. Peng XV; Marcinak JF; Raanan MG; Cao C Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939 [TBL] [Abstract][Full Text] [Related]
32. Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study. Sato A; Takei M; Hiramatsu K; Takeda T; Miyamoto T; Yamazaki M; Sato Y; Komatsu M J Clin Med Res; 2019 Jan; 11(1):15-20. PubMed ID: 30627273 [TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study. Gupta S; Khajuria V; Tandon VR; Mahajan A; Gillani ZH Perspect Clin Res; 2015; 6(3):163-8. PubMed ID: 26229753 [TBL] [Abstract][Full Text] [Related]
34. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus. Xie J; Li N; Jiang X; Chai L; Chen JJ; Deng W Diabetes Metab Syndr Obes; 2019; 12():519-526. PubMed ID: 31114280 [No Abstract] [Full Text] [Related]
35. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781 [TBL] [Abstract][Full Text] [Related]
36. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Hollander P; Liu J; Hill J; Johnson J; Jiang ZW; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B Diabetes Ther; 2018 Feb; 9(1):193-207. PubMed ID: 29282633 [TBL] [Abstract][Full Text] [Related]
37. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. Ito D; Inoue K; Saito D; Hamaguchi K; Kaneko K; Sumita T; Inukai K; Inoue I; Shimada A Diabetes Ther; 2021 Dec; 12(12):3201-3215. PubMed ID: 34709582 [TBL] [Abstract][Full Text] [Related]
38. Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. Chawla S; Kaushik N; Singh NP; Ghosh RK; Saxena A J Pharmacol Pharmacother; 2013 Jan; 4(1):27-32. PubMed ID: 23662021 [TBL] [Abstract][Full Text] [Related]
39. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus. Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Yoon KH; Shin JA; Kwon HS; Lee SH; Min KW; Ahn YB; Yoo SJ; Ahn KJ; Park SW; Lee KW; Sung YA; Park TS; Kim MS; Kim YK; Nam MS; Kim HS; Park IeB; Park JS; Woo JT; Son HY Diabetes Metab J; 2011 Feb; 35(1):26-33. PubMed ID: 21537410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]